Evidence map›Paper›PMID 35901360›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Newly Substituted Anilino-Fluoroquinolones with Proliferation Inhibition Potential against a Panel of Cancer Cell Lines.

Mohammed Ameen Fouad Salih, Yusuf Al-Hiari, Violet Kasabri, Rula Darwish, Hamza Abumansour, Laurance Bourghli, Sundus Al Alawi, Rabab Albashiti

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Selected Statins as Dual Antiproliferative-Antiinflammatory Compounds.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohammed Ameen Fouad SalihSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Yusuf Al-HiariSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Violet KasabriSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.ORCID 0000-0003-1927-0193
Rula DarwishSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Hamza AbumansourFaculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O.Box 130 Amman 11733 Jordan.
Laurance BourghliFaculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O.Box 130 Amman 11733 Jordan.
Sundus Al AlawiSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
Rabab AlbashitiSchool of Pharmacy, University of Jordan, Amman 11942, Queen Rania Street, Jordan.
University of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFrom a chemistry point of view, we hypothesized that superlative dual cytotoxicity-radical scavenging bioefficacies of series 4 FQs correlate to their acidic groups and C8-C7 ethylene diamine Chelation Bridge. METHODOLOGY: Newly synthesized 16 lipophilic-acid chelating FQs have been screened for in vitro duality of proliferation inhibition and radical scavenging capacities.

resultsSubstantially in LPS prompted RAW264.7 macrophages inflammation, IC50 values (µM) in the ascending order of  new FQs' NO scavenging/antiinflammation capacity were 4e<4b<3d<4f<5c0.05). In comparison to classical and robust antineoplastic agent cisplatin and unlike triazoloFQs; nitroFQs (3a, 3b and 3f) and the reduced FQs (4a, 4c, 4d and 4e) exerted antiproliferation IC50 values <50 µM in leukaemia K562. Besides nitroFQ 3, the reduced FQs (4c and 4f) exhibited antineoplastic IC50 values <50 µM in lung A549 carcinoma. NitroFQ 3c and reduced FQs 4b, 4c, and 4f in breast MCF7 and reduced 4c in pancreatic PANC1 had reduction of viability IC50 values <50 µM. NitroFQ 3e, reduced FQs 4b and, 4c and triazoloFQ 5a exerted antiproliferation IC50 values <50 µM in breast T47D cells. Also nitroFQ 3e, reduced FQ 4c and triazoloFQ 5f exhibited antineoplastic IC50 values <50 µM in PC3 prostate cancer cells. Exceptionally triazoloFQ 5a, but neither nitro- nor reduced FQs, had cytotoxicity IC50 value <50 µM in resistant melanoma A375 cells. Unequivocally 4b antineoplastic effectiveness linked with its radical scavenging and antiinflammation effects while 3d and 5c lacked matching antiproliferation potentialities to their exquisite antiinflammation capacities. Explicitly reduced 4e and 4f exerted antiinflammation-selective cytotoxicity duality in vitro.

conclusionCollectively, this work reveals lipophilic-acidic chelator FQs as authentic agents for the repurposing approach in anticancer chemotherapy/prevention.

Indexed as

Antineoplastic AgentsLung NeoplasmsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFluoroquinolonesHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsFluoroquinolonesAntiinflammation and antiCancerCisplatinFluoroquinolones and TriazoloquinolonesNO-radical scavengingSulphorodhamine B and Greiss assay

Identifiers

PMID35901360
PMCPMC9727339
OpenAlexW4288388823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.